Rituximab biosimilar (Zhejiang Teruisi Pharmaceutical)

利妥昔单抗生物类似药（浙江特瑞思药业）

Report date: 2022/07/15 15:58:59

Base Information

Drug NameRituximab biosimilar (Zhejiang Teruisi Pharmaceutical)

Drug Alias Name重组人鼠嵌合抗CD20单克隆抗体（浙江特瑞思药业）利妥昔单抗生物仿制药（浙江特瑞思药业）TRS001

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4]

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesZhejiang Teruisi Pharmaceutical Inc

China Registration ClassN/A

Develop Information

Active CompaniesZhejiang Teruisi Pharmaceutical Inc

Inactive CompaniesN/A

Active IndicationsLymphoma

Inactive IndicationsN/A

Other Information

ATC CodeL01XC02